under some special condition, we might test the previous samples. In addition, the curative effect of crizotinib in the treatment of the lung cancer patient with EML6-ALK and FBXO11-ALK double fusion provided a certain reference for the patients with such gene alteration.
Immune Checkpoint Inhibitors in HIV-Positive Patients With NSCLC: Is it Time for Outlining a Protocol?
To the Editor: In a recent publication, Ostios-Garcia et al. 1 focused on the safety and efficacy of programmed death receptor-1( PD-1) inhibitors among HIV-positive patients with advanced NSCLC. They described seven patients suffering from metastatic NSCLC and HIV infection who had undergone treatment with the PD-1 inhibitors nivolumab or pembrolizumab. 1 They conclude that nivolumab and pembrolizumab can be safe and effective among patients with HIV. 1 However, they suggest that larger studies will be needed to verify the overall safety and efficacy of immune checkpoint inhibitors among cancer patients with HIV. 1 The therapeutic inhibition of the PD-1/ programmed death ligand 1 (PD-L1) axis has emerged as a therapeutic approach to NSCLC in recent years. 1 Several immune checkpoint inhibitors have been approved for the treatment of advanced PD-L1-positive NSCLC 1 . HIV infection has been typically considered an exclusion criterion for immunotherapy as the PD-1/PD-L1 axis plays a key role in regulation of the immune system. 1 Currently, the mortality rate connected with AIDS is decreasing as a result of the remarkable improvements in antiretroviral therapy. 2 HIV infection appears to increase lung cancer (LC) risk, with substantial evidence that this effect is independent of smoking. 2 LC is the most frequently occurring malignancy in HIV-positive patients. 2 Telomere length of tumor tissues seems to be an independent prognostic factor in patients with surgically resected early-stage NSCLC. 3 Patients with the shortest telomere length appear to experience a significantly worse overall survival and disease-free survival compared with patients with longer telomeres. 3 Telomere shortening results in genomic instability that drives oncogenesis by activating telomerase. 3 Decreased peripheral leukocyte telomere length has long been associated with HIV. 4 HIV infection has also been connected with an increased risk of chronic obstructive pulmonary disease independent of cigarette smoke exposure. 3 It has detected that telomere shortening also occurs in the lungs, with significant decreases in telomere length observed in small airway epithelial cells. 4 It has been evidenced that HIV-1-specific CD8þT cells from HIV-1 controllers are characterized by long telomeres and high levels of constitutive telomerase activity, whereas HIV-1-specific CD8þT cells from HIV-1 progressors show telomere shortening with limited telomerase activity. 5 It has been suggested that telomere shortening plays a causal role in the functional deficiency of HIV-1-specific CD8þT cells in chronic progressive infection. 5 Telomere lengths and telomerase activities have been documented to be actively increased by blocking the PD-1/PD-L1 pathways in HIV-1-specific CD8þT cells from progressors suggesting an active reversibility of the process of telomere shortening. 5 Taken together, I hypothesize that the therapeutic benefits of immune checkpoint inhibitors in HIV-infected patients with NSCLC may be mediated by increasing telomere length by blocking the PD-1/PD-L1 pathway, given that telomere shortening and telomerase activity relate to the pathologic basis of both NSCLC and HIV infection. Thus, I propose that it is time for outlining a standardized protocol for treatment of HIV-positive patients with NSCLC. Moreover, I advise that further investigations are needed to better define the interplay between immunotherapy and telomere length in HIV and LC.
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